Metastatic castration-resistant prostate cancer (mCRPC) is a global health issue with a poor prognosis.

Putative predictive biomarkers, such as homologous recombination repair (HRR) mutations, would benefit the treatment.

Poly-ADP ribose polymerase (PARP) inhibitors represent a promising treatment opportunity in patients with mCRPC harboring HRR mutations.

Genomic and proteomic profiling and liquid tumor profiling will play a vital role in predicting therapeutic efficiency in patients with mCRPC with rarer mutations.

Access to real-world data would benefit clinicians and researchers in terms of increasing understanding of the rarer genes and optimizing both treatment selection and treatment sequencing patterns in mCRPC.